Trial Profile
A global named patient use program assessing effects of afatinib in heavily pretreated patients with HER2 mutation-positive advanced non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2017
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Oct 2017 New trial record
- 12 Sep 2017 Results (n=28; as of May 2017) presented at the 42nd European Society for Medical Oncology Congress